Lessons Learned from Clinical Trials in Acute Heart Failure: Phase 3 Drug Trials

Heart Failure Clinics

Volumn 7, Issue 4, 2011, Pages 451-456

  O'Connor, Christopher M ^a   Fiuzat, Mona ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute heart failure; Efficacy; Endpoints; Phase 3 clinical trials; Safety

Indexed keywords

LEVOSIMENDAN; MILRINONE; NESIRITIDE; ROLOFYLLINE; TEZOSENTAN; TOLVAPTAN; VASOPRESSIN;

ACUTE HEART FAILURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FAILURE; LENGTH OF STAY; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION; PROBABILITY; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPONSE VARIABLE; REVIEW; SAMPLE SIZE; STUDY DESIGN; SYSTEMATIC ERROR; TREATMENT DURATION; TREATMENT RESPONSE; VALIDITY; WELLBEING;

ACUTE DISEASE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYNDROME;

EID: 80052928000     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.06.013     Document Type: Review

References (10)

1. Fonarow G.C., Abraham W.T., Albert N.M., et al. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. J Card Fail 2007, 13:722-731.
2. Abraham W.T., Adams K.F., Fonarow G.C., et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005, 46:57-64.
3. Colucci W.S., Elkayam U., Horton D.P., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000, 343:246-253.
4. Cuffe M.S., Califf R.M., Adams K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547.
5. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007, 297:1883-1891.
6. McMurray J.J., Teerlink J.R., Cotter G., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007, 298:2009-2019.
7. Gheorghiade M., Gattis W.A., O'Connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291:1963-1971.
8. Cotter G., Dittrich H.C., Weatherley B.D., et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008, 14:631-640.
9. Massie B.M., O'Connor C.M., Metra M., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010, 363:1419-1428.
10. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011, 365:32-43.